Page 6 - C Diff News Today

If hospitals want to prevent Clostridium difficile infections, its essential they adopt antimicrobial stewardship programs, according to updated guidance from five medical organizations. 

As we wrap up yet another month, let's take stock of the latest regulatory news that have been dominating the headlines, and gear up for what's ahead in April, which is observed as the National Cancer Control Month.

Dear Readers: When I said I would write about the microbiome this week, there were some raised eyebrows. My friend Ken said, “Of course ... what is that?"

Researchers have identified a compound that prevents C. diff infection caused by multiple strains of the bacterium and are using it to develop new drug candidates that target the disease. 

Researchers review existing data on Clostridioides difficile infections among United States residents.

Not all probiotics are created equal. In a new study, researchers found that certain enzymes within a class known as bile salt hydrolases (BSHs) can restrict Clostridioides difficile (C. diff.) colonization by both altering existing bile acids and by creating a new class of bile acids within the gut's microbial environment.

New research from the University of Virginia School of Medicine and collaborators reveals how microorganisms found in our guts can worsen dangerous C. difficile infections.

Clostridioides difficile, often referred to as C. difficile or C. diff, is a bacterium that causes severe intestinal illness and, as its name suggests, can be difficult to study and treat.

The Peggy Lillis Foundation announced its annual gala to kick off its fourth See C. Diff campaign as part of C. Diff Awareness Month.

Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the...